Medivir AB (publ)
0GP7.L
London Stock Exchange1.79
SEK
+0.00
- -
Medivir AB (publ)
0GP7.L
(London Stock Exchange)
Recent
price
1.79
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Medivir AB (publ) is a Swedish biotechnology company specializing in the research, development, and commercialization of innovative pharmaceuticals primarily for oncology and diseases with high unmet medical needs. The company’s main products and development pipeline include fostroxacitabine bralpamide (fostrox) for liver cancer (hepatocellular carcinoma); Remetinostat for cutaneous T-cell lymphoma and basal cell carcinoma; MIV-711 targeting osteoarthritis as a cathepsin K inhibitor; MIV-818 for liver cancer treatment; and Birinapant and IGM-8444 in development for solid tumors. Medivir markets Xerclear under the brand Zoviduo for labial herpes and has a strong focus on protease inhibitors and targeted cancer therapies. Its business model emphasizes in-house drug development complemented by strategic partnerships, such as collaborations with Eisai for clinical trials evaluating fostrox in combination with Lenvima for advanced liver cancer and licensing agreements with Vetbiolix, Tango Therapeutics, and Ubiquigent Limited. Founded in 1988 and headquartered in Huddinge, Sweden, Medivir operates internationally with a focus on Nordic markets and global clinical development initiatives. The company has recently shifted focus towards oncology, reflecting strategic expansion into advanced cancer therapeutics. Key recent developments include the FDA granting orphan drug designation for its candidate MIV-711 for the treatment of Osteogenesis Imperfecta, entry into a collaboration and supply agreement with Eisai in 2024 to advance Phase 2b studies involving fostrox and Lenvima, and publication of clinical proof-of-concept data by its partner Vetbiolix for VBX-1000 (formerly MIV-701). In 2024, Medivir also secured a SEK 30 million loan facility to support ongoing clinical development activities. The company maintains a global CRO partnership for its liver cancer studies and continues to explore licensing and partnering opportunities for Remetinostat and MIV-711 to accelerate clinical adoption and commercial potential. Medivir is recognized for its balanced project portfolio, scientific expertise, and collaborative culture, aiming to bring innovative drugs to patients with cancer and other serious diseases. The company combines in-house project advancement with strategic external collaborations to extend its product pipeline and enhance shareholder value. Its current focus remains on advancing oncology drug candidates through late-stage clinical development with a view toward regulatory approval and commercialization.